Summit Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Summit Therapeutics Inc.
Former names
Summit Corp plc
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Headquarters city
Miami
Headquarters state / province
Florida
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SMMT
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001599298
EIN
37-1979717

Board of directors

Follow this board

Chief executives

Mahkam Zanganeh · Chief Executive Officer
Dates unknown
Robert W. Duggan · Co-Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 12, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 5 other boards.

Network of Summit Therapeutics Inc.'s board connections Pulse Biosciences Inc Pulse Biosciences Inc Puma Biotechnology Inc Puma Biotechnology Inc Seer Inc. Seer Inc. Upstart Holdings Inc. Upstart Holdings Inc. Zymeworks Inc. Zymeworks Inc. Alessandra Cesano Alessandra Cesano Jeff Huber Jeff Huber Mahkam Zanganeh Mahkam Zanganeh Manmeet Singh Soni Manmeet Singh Soni Mostafa Ronaghi Mostafa Ronaghi Robert W. Duggan Robert W. Duggan Summit Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$114,616,599
9 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jun 12, 2026 Mahkam Zanganeh Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +3,810,000 $13.12 $49,987,200
Jun 12, 2026 Robert W. Duggan Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +3,810,000 $13.12 $49,987,200
Jun 4, 2026 Robert W. Duggan Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +100,000 $14.60 $1,460,000
Jun 4, 2026 Mahkam Zanganeh Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +100,000 $14.60 $1,460,000
Jun 4, 2026 Manmeet Singh Soni Director, Officer (COO and CFO) Open-market purchase +25,000 $14.46 $361,500
Jun 4, 2026 Manmeet Singh Soni Director, Officer (COO and CFO) Open-market purchase +25,000 $14.43 $360,750
Oct 21, 2025 Yu Xia Director Open-market purchase +533,617 $18.74 $9,999,983
Oct 21, 2025 Anand Bhaskar Officer (Chief Accounting Officer) Grant or award +26,680 $18.74 $499,983
Oct 21, 2025 Manmeet Singh Soni Director, Officer (COO and CFO) Grant or award +53,361 $18.74 $999,985
Oct 21, 2025 Robert W. Duggan Director, Officer (Co-Chief Executive Officer), 10% owner Grant or award +13,980,789 $18.74 $261,999,986
Oct 21, 2025 Mahkam Zanganeh Director, Officer (Co-Chief Executive Officer), 10% owner Grant or award +266,808 $18.74 $4,999,982
Oct 21, 2025 Robert W. Duggan Director, Officer (Co-Chief Executive Officer), 10% owner Grant or award +266,808 $18.74 $4,999,982
Oct 21, 2025 Mahkam Zanganeh Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +26,680 $18.74 $499,983
Oct 21, 2025 Robert W. Duggan Director, Officer (Co-Chief Executive Officer), 10% owner Open-market purchase +26,680 $18.74 $499,983
Oct 21, 2025 Mahkam Zanganeh Director, Officer (Co-Chief Executive Officer), 10% owner Grant or award +13,980,789 $18.74 $261,999,986

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.